PDS Biotechnology (PDSB) Competitors

Protalix BioTherapeutics (NYSE:PLX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.

Do institutionals and insiders believe in PLX or PDSB?

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 6.3% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 9.5% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has preferable earnings & valuation, PLX or PDSB?

Protalix BioTherapeutics has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$53.40M	4.35	$8.31M	$0.03	99.17
PDS Biotechnology	N/A	N/A	-$42.94M	-$1.03	-1.32

Does the MarketBeat Community prefer PLX or PDSB?

PDS Biotechnology received 63 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 80.00% of users gave Protalix BioTherapeutics an outperform vote while only 70.75% of users gave PDS Biotechnology an outperform vote.

Company	Underperform	Outperform
Protalix BioTherapeutics	Outperform Votes 12 80.00%	Underperform Votes 3 20.00%
PDS Biotechnology	Outperform Votes 75 70.75%	Underperform Votes 31 29.25%

Does the media refer more to PLX or PDSB?

In the previous week, PDS Biotechnology had 2 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 5 mentions for PDS Biotechnology and 3 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 1.32 beat PDS Biotechnology's score of 0.85 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protalix BioTherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PDS Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, PLX or PDSB?

Protalix BioTherapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

Is PLX or PDSB more profitable?

PDS Biotechnology has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
PDS Biotechnology	N/A	-139.57%	-67.22%

Do analysts rate PLX or PDSB?

Protalix BioTherapeutics presently has a consensus price target of $15.00, indicating a potential upside of 404.20%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 561.28%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PDS Biotechnology	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Summary

PDS Biotechnology beats Protalix BioTherapeutics on 11 of the 18 factors compared between the two stocks.